DCSIMG

Ethicon develops the suture of the future at €80 million Limerick plant

Dan Wildman, president of Ethicon Biosurgery with ministers Michael Noonan and Richard Bruton at Monday's jobs announcment [Picture: Michael Cowhey]

Dan Wildman, president of Ethicon Biosurgery with ministers Michael Noonan and Richard Bruton at Monday's jobs announcment [Picture: Michael Cowhey]

 

A SENIOR executive with Johnson & Johnson has said the local pool of talent and the multinational’s positive experience of Limerick were crucial in selecting the city for an {http://www.limerickleader.ie/news/420-new-jobs-for-limerick-in-80m-investment-1-5999718|€80 million} investment that will create 270 jobs.

Dan Wildman, worldwide president of Ethicon Biosurgery, a J&J company, said that the corporation already employed 2,600 people in Ireland. And he expects there will be significant spin-off jobs for contractors and suppliers supporting the new manufacturing plant Ethicon will open in Plassey next year.

“For every J&J job in Ireland, there are about 2.4 additional jobs supported in the country, for example in plastics, metals manufacturing, construction companies and so on. You can multiply that out to get a feel for the impact we have here in Ireland,” Mr Wildman said.

That J&J already owned property near its Vistakon plant was another factor in favour of Limerick’s selection as the new home for Ethicon.

It is at the Limerick plant that the company will manufacture a revolutionary surgical product that stops bleeding during operations.

And such a product was in keeping with J&J’s long history, Mr Wildman explained.

“We make most of the world’s sutures and the suture was in the original product catalogue for J&J well over 150 years ago. So it is a legacy business of the company that we are now, with businesses like Ethicon Biosurgery, taking to the next level from a science, capability and technology standpoint.

“It is a combination product so it combines biomaterials, traditionally medical devices, with biologics, traditionally pharma. We brought those two things together into this new technology and that combination results in an effectiveness an efficacy that those two things could not do independently. The magic is when you combine them and that is new science and new art in the industry,” Mr Wildman said.

The technology delivers the proteins naturally present in blood and necessary for clotting to stop bleeding during surgery.

 

Comments

 
 

Back to the top of the page